Perspectives
Biologics dominate treatment costs for Crohn’s and ulcerative colitis
BIologic drug therapy makes up more than 70% of the total cost of care for either condition
October 19, 2019Biologic therapy makes up more than 70% of the total cost of care for members with either Crohn’s disease (CD) or ulcerative colitis (UC)
Crohn’s disease and ulcerative colitis are the two major types of inflammatory bowel disease (IBD). This study determined that biologic therapy makes up most of the annual total pharmacy and medical costs. It shows real-world prevalence, utilization, and total health care costs to improve understanding of the conditions. It adds Prime’s insights to the industry dialogue tying drug cost to value. But it’s clear that it is not possible to obtain a direct medical care cost offset to biologic therapy in IBD.
Related news
Perspectives
March 30, 2023
Drug oversupply, or stockpiling, due to overlapping drug refills can cause unnecessary drug costs
If you have a chronic condition, your pharmacy may notify you advance of…
Perspectives
March 28, 2023
Biosimilars are at the door, Part 3
News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…
Perspectives
March 27, 2023
Specialty Drug Pipeline Update: March 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…